Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 11/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.37 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3366312 | 0.90 | TSHR (0.43) | TSHRPTGDR2MEN1KMT2AKCNH2 | |
| SCHEMBL13428313 | 0.88 | PTGDR2 (0.40) | TSHRPTGDR2MEN1KMT2ALPAR1 | |
| SCHEMBL1922879 | 0.86 | PTGDR2 (0.43) | PTGDR2MEN1KMT2AKCNH2ALDH1A1 | |
| SCHEMBL16501872 | 0.86 | MEN1 (0.46) | TSHRPTGDR2MEN1KMT2ALPAR1 | |
| SCHEMBL1922570 | 0.83 | PTGDR2 (0.42) | TSHRPTGDR2MEN1KMT2ALPAR1 | |
| SCHEMBL1922921 | 0.81 | MEN1 (0.43) | TSHRPTGDR2MEN1KMT2AALDH1A1 | |
| SCHEMBL1922427 | 0.81 | PTGDR2 (0.53) | PTGDR2 | |
| SCHEMBL1922579 | 0.81 | PTGDR2 (0.42) | TSHRPTGDR2MEN1KMT2ALPAR1 | |
| SCHEMBL13428384 | 0.79 | ALDH1A1 (0.39) | TSHRPTGDR2MEN1KMT2ALPAR1 | |
| SCHEMBL16496997 | 0.79 | MEN1 (0.39) | TSHRPTGDR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312974-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | claimed |
| US-20110312974-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110312974-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| WO-2010037059-A2 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312974-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | TSHR 613/4885PTGDR2 2/4885MEN1 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.